Physician profile
Ebrahim Issa
NPI 1578524864
$5,208.33
in general payments reported to CMS, 2019-2025
27 companies · $839 in 2025
The $839 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2020: $695 · 2021: $592 · 2022: $766 · 2023: $902 · 2024: $709 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,361 · Education: $88.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,360.52 |
| Education | $88.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,512.50 | 2021-2025 | Micra, Aurora Ev-Icd Mri Surescan, Symplicity G3 |
| Amgen INC. | $701.65 | 2019-2025 | Repatha, Repatha |
| Medtronic Vascular, INC. | $493.36 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $341.78 | 2019-2025 | Farxiga, Wainua |
| Novartis Pharmaceuticals Corporation | $307.99 | 2020-2025 | |
| Abbott Laboratories | $264.41 | 2019-2023 | Aveir, Merlin@Home |
| Merck Sharp & Dohme LLC | $249.79 | 2021-2024 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $166.67 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.62 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $149.70 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $133.23 | 2021-2025 | |
| Boston Scientific Corporation | $124.93 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $122.09 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $96.65 | 2022-2025 | |
| Philips North America LLC | $60.01 | 2022-2024 | (Ck4) Mcot |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $53.48 | 2019 | |
| Gilead Sciences, INC. | $51.24 | 2019 | |
| Esperion Therapeutics, INC. | $44.47 | 2021-2025 | Nexletol |
| Lundbeck LLC | $40.28 | 2020 | |
| Heartflow, INC. | $35.49 | 2022-2024 | |
| Lantheus Medical Imaging, INC. | $20.09 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $16.20 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, Ltd. | $14.66 | 2023 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $13.65 | 2021 | |
| Glaxosmithkline, LLC. | $13.57 | 2024 | Trelegy Ellipta |
| Arbor Pharmaceuticals, INC. | $13.36 | 2021 | |
| Cvrx, INC. | $10.46 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ebrahim Issa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.